DAFNA Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

DAFNA Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-75,000	Closed	-$1.73M	–	95
2020 Q4	$1.73M	Hold	75,000	–	–	0.51%	42
2020 Q3	$764K	Hold	75,000	–	–	0.25%	62
2020 Q2	$1.12M	Hold	75,000	–	–	0.32%	53
2020 Q1	$914K	Hold	75,000	–	–	0.38%	53
2019 Q4	$1.19M	Hold	75,000	–	–	0.41%	55
2019 Q3	$921K	Hold	75,000	–	–	0.35%	60
2019 Q2	$990K	Buy	+75,000	New	+$1.09M	0.37%	59

DAFNA Capital Management's PRVL Position: Q1 2021 in Review

DAFNA Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 75,000 shares — an estimated $1.73M sold.

DAFNA Capital Management first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $1.73M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

DAFNA Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
DAFNA Capital Management sold 75,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1.73M.
DAFNA Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
DAFNA Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $1.73M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.